Financial Data and Key Metrics Changes - In Q4 2025, total revenue grew 14% year-over-year to $44.6 million, with a sequential increase of 16% [5][25] - For the full year 2025, total revenue reached $160 million, representing a 4% growth over 2024 [5][29] - Non-GAAP gross margin improved to 40% in Q4 2025, up from 31% in Q4 2024, and for the full year, it was also 40%, compared to 33% in 2024 [30][22] - Non-GAAP operating expenses decreased to $56.2 million in Q4 2025, down 18% year-over-year, and for the full year, they were $229.9 million, down from $289.2 million in 2024 [31][22] Business Line Data and Key Metrics Changes - Consumable revenue in Q4 2025 increased 15% year-over-year to $21.6 million, driven by a growing installed base and consistent system utilization [25][6] - Instrument revenue rose 13% in Q4 2025 to $17.3 million, primarily due to increased shipments of Vega systems [26] - For the full year 2025, consumables revenue increased 16% to $82 million, while instrument revenue decreased 18% to $53.8 million [29] Market Data and Key Metrics Changes - Revenue from the Americas increased 3% to $20.7 million in Q4 2025, while Asia Pacific revenue grew 4% to $9.3 million, and EMEA revenue surged 45% to $14.6 million [27][28] - The strong growth in EMEA was attributed to increased clinical adoption and higher shipments of Vega instruments [28] Company Strategy and Development Direction - The company aims to improve the economics of HiFi sequencing through the launch of SparkNex and multi-use smart cells, targeting increased market penetration [37] - Focus areas include accelerating clinical adoption in rare disease, oncology, and carrier screening, as well as enabling population-scale sequencing studies [37] - The company plans to leverage AI to unlock unique biological insights from multi-omic HiFi data [37] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued growth in clinical markets, particularly in rare disease and whole genome sequencing, despite a challenging academic funding environment [9][52] - The outlook for 2026 projects revenue between $165 million and $180 million, representing approximately 8% growth at the midpoint [33] - Management expects non-GAAP gross margin to improve by 100-400 basis points in 2026, driven by a higher consumables mix and the introduction of SparkNex [34] Other Important Information - The company ended 2025 with approximately $280 million in cash and investments, down from $389.9 million at the end of 2024 [23][33] - The recent sale of short-read sequencing assets for approximately $48 million is expected to strengthen the balance sheet and extend the cash runway [24] Q&A Session Summary Question: What should we expect OUS to do this year from a clinical growth perspective? - Management noted strong growth in clinical markets, particularly in EMEA, with many customers moving from pilot testing to broader clinical adoption [52] Question: What is the biggest opportunity to reduce OpEx spending this year? - Management indicated a focus on managing G&A expenses and R&D while maintaining funding for critical programs [66] Question: Did you see any budget flush, particularly from Europe in full Q25? - Management did not observe significant budget flush but noted some opportunistic purchasing [51]

Summary of Pacific Biosciences of California Conference Call Company Overview - **Company**: Pacific Biosciences of California (NasdaqGS:PACB) - **Industry**: Biotechnology, specifically focused on long-read sequencing technology solutions - **Key Products**: Revio and Vega instruments Core Points and Arguments 1. **Transition to Responsible Growth**: The company is transitioning from a growth-at-all-costs strategy to a more disciplined approach that balances growth with operating efficiency and margin improvement [9][12][15] 2. **Financial Position**: The company has a strong financial position with nearly $300 million available for investment in next-generation products and long-read technology [15] 3. **Q3 Performance**: Q3 revenue was $38 million, slightly below expectations of $40 million, primarily due to timing issues with the Vega instrument [18][21] 4. **Product Pipeline**: The company is focusing on product extensions and new launches, including the Spark NX and Pure Target, which are expected to drive future growth [8][35][41] 5. **Market Dynamics**: The company is seeing increased interest from both existing and new customers, particularly in clinical applications, as they move towards long-read sequencing [38][81] 6. **Pricing Strategy**: The company is implementing strategic pricing adjustments, including discounts for key accounts, to penetrate clinical markets and increase utilization [26][27][49] 7. **Gross Margin Improvement**: The company aims to improve gross margins above 40% in 2026 through better product mix, in-house manufacturing, and improved yield on consumables [56][60][62] 8. **Operational Efficiency**: The company plans to maintain flat to declining operating expenses while investing in key areas like R&D for ultra-high throughput machines [62][64] 9. **Geographic Revenue Mix**: The company is experiencing growth in EMEA and Asia-Pacific regions, with a focus on expanding its sales force in these areas [78][80] 10. **Clinical Growth**: Clinical applications now account for approximately 15% of revenue, with significant growth expected from recent partnerships and product approvals [81][82] Additional Important Insights - **AI and Data Utilization**: The integration of AI and improved computational capabilities is expected to enhance the value of long-read data, driving demand for PacBio's solutions [16][17] - **Policy Environment**: The funding environment for academic customers has stabilized, which may lead to increased sales of Revio instruments [71][75] - **Customer Engagement**: The company is actively engaging with academic and NIH-funded customers, who are showing renewed interest in long-read technology [72][74] - **Future Outlook**: The company is optimistic about its growth trajectory, particularly with upcoming product launches and a more favorable policy environment [68][76]

Financial Performance - PacBio Q1 2025 revenue was $37.2 million[9,43], a decrease of 8% year-over-year compared to $38.8 million in Q1 2024[47] - Q1 2025 consumable revenue reached a company record of $20.1 million, representing a 26% year-over-year growth[14] - The company's Q1 2025 non-GAAP gross margin was approximately 40%, an increase from approximately 33% in Q1 2024[50] - Non-GAAP operating expenses for Q1 2025 were $61.7 million, a 29% decrease compared to Q1 2024[50] - PacBio anticipates revenue between $150 million and $170 million for 2025, representing approximately 4% growth at the midpoint[20,55] Product and System Updates - Q1 instrument revenue was $11.0 million, lower year-over-year due to increased uncertainty in academic funding[9] - PacBio shipped 12 Revio systems and 28 Vega systems in Q1 2025[9] - Approximately 50% of Revio and Vega systems were shipped to new customers[9,28] - The annualized Revio pull-through for Q1 2025 was $236,000[14,43] - Nearly 90% of Revio reagent kit shipments in Q1 2025 utilized SPRQ chemistry[23] Strategic Initiatives - PacBio implemented a restructuring plan in April, expecting to lower annualized non-GAAP operating expenses by $45 million to $50 million by year-end[21]